Radiation Therapy Targeting Metastatic Sites Compared to Standard Prostate Treatment with Long-term Hormone Therapy for Men with Newly Diagnosed Oligometastatic Prostate Cancer
Led by Case Comprehensive Cancer Center · Updated on 2026-09-15
200
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating if adding radiation therapy targeted to metastatic sites metastasis-directed radiotherapy or MDRT at diagnosis improves control of metastatic prostate cancer compared to the usual treatment. This is a phase 2 trial focused on men with newly diagnosed metastatic prostate cancer receiving long-term hormone therapy. The study aims to compare standard care alone versus standard care plus MDRT to assess disease control benefits.
Participants receive standard systemic therapy with androgen deprivation therapy ADT and androgen receptor signaling inhibitors ARSI for 12 months. Local therapy includes radiotherapy RT to the prostate or surgery to remove the prostate radical prostatectomy. Those randomized to the MDRT arm will also receive targeted radiotherapy to metastatic lesions by Week 24. Local therapy should be completed by Week 20.
During the 12-month study period, participants undergo treatment and regular evaluations including imaging to assess disease progression. Researchers measure failure-free survival up to 5 years after treatment to evaluate effectiveness. Additional outcomes include overall survival, progression-free survival, quality of life assessments, and skeletal-related events. Participants will be followed by their doctors for up to five years according to standard care after study completion.
CONDITIONS
Brief Title
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Research Team
A
Angela Y Jia, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
SOC + MDRT
SOC
Systemic Intensification
What it is
Standard systemic therapy plus metastasis‑directed radiotherapy to all lesions
Standard systemic therapy including ADT with or without androgen‑receptor signaling inhibitors and local therapy as per treating physician
ADT with added systemic therapy such as ARSI or chemotherapy is current guideline‑recommended treatment for metastatic hormone‑sensitive prostate cancer
Role in the trial
Experimental arm evaluating the addition of MDRT
Control arm following standard practice without MDRT
Represents external treatment intensification not studied in this trial
Primary use
To treat oligometastatic disease by combining systemic therapy with local treatment of metastases
To treat oligometastatic prostate cancer with systemic therapy
To treat metastatic hormone‑sensitive prostate cancer by intensifying systemic therapy
How it is given or performed
Adds metastasis‑directed radiotherapy to all lesions by Week 24 alongside systemic therapy
ADT plus ARSI and/or local definitive therapy given per physician discretion
ADT plus systemic intensification (e.g. ARSI or chemotherapy) without MDRT
Evidence status
MDT plus ADT shows promise in phase 2 trials for improved progression outcomes but not yet proven in randomized phase III
SOC efficacy based on established guideline‑supported evidence for ADT±ARSI
Intensified systemic therapy improves survival and progression‑free outcomes in metastatic hormone‑sensitive prostate cancer
Important risks
Adds radiation‑related side effects from MDRT along with systemic therapy risks
Risks related to systemic therapy (hormonal and ARSI side effects) and local definitive therapy per physician choice
Increased systemic toxicity associated with combination systemic regimens
Important limitations
Uncertain long‑term benefit; optimal radiation regimen and integration with systemic therapy unknown
Standard systemic therapy does not target metastatic lesions directly
Systemic intensification may increase toxicity and accessibility concerns
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
MALE
Eligibility Criteria
You may qualify if you...
Male participants aged 18 years or older
ECOG performance status of 0 or 1
Histologic confirmation of prostate adenocarcinoma with metastatic disease on imaging
Newly diagnosed with no prior treatment to primary prostate cancer except limited hormone therapy started within 30 days
Oligometastatic disease defined by specific imaging criteria
Adequate organ and marrow function
Medically fit for treatment and able to follow up
Willing and able to provide written informed consent
You will not qualify if you...
Castration resistant prostate cancer
Visceral or intracranial metastases
Participation in other investigational cancer treatments or concurrent cancer protocols
Unable to tolerate lying flat for imaging or radiotherapy
Prior definitive treatment to primary prostate cancer or pelvis
Uncontrolled intercurrent illness including active infection, heart failure, unstable angina, arrhythmia, uncontrolled diabetes, pituitary or adrenal dysfunction, or psychiatric illness
Recent history of other active malignancy except certain low-risk cancers
Active Crohn's disease or ulcerative colitis despite treatment
Refusal to sign informed consent
Any condition deemed by investigator to preclude participation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Approximately 12 months
Participants receive standard hormone therapy and local prostate treatment (radiotherapy or surgery). Some participants also receive targeted metastasis-directed radiotherapy to metastatic sites.
Regular visits up to Week 24 for therapy completion
Follow-up
Duration - Up to 5 years
Participants are followed by their doctors for up to 5 years after treatment to monitor disease progression and overall health.
Periodic visits as part of standard care
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of 177Lu-PSMA as an Additional Treatment for High and Very High Risk Prostate Cancer After Radiation and Hormone Therapy
Phase 1b Study of 177Lu-PSMA-617 With Liver-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
Using 18F-PSMA-1007 PET-CT to Guide Targeted Focal Therapy for MRI-Invisible Prostate Cancer
A Prospective Phase II Study Evaluating PET-Directed Treatment in Men with Localized Intermediate-Risk Prostate Cancer
Evaluation of 18F-PSMA-1007 PETCT Imaging Safety and Effectiveness in Adult Men with Prostate Cancer
Combining One MR-Guided HDR Brachytherapy and One SABR Treatment
for Favorable Risk Prostate Cancer
in a Phase 23 Study
Study of 4-Aminopyridine to Improve Nerve Recovery After Robot-Assisted Radical Prostatectomy in Men with Prostate Cancer
Phase III Study of 64Cu-GRIP B PET Imaging for Detecting Granzyme B in Adults with Advanced Genitourinary and Other Solid Tumors
Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 PETCT Scans for Detecting Primary Prostate Cancer in Men
Using 68Ga-PSMA PETMRI and mpMRI to Detect Prostate Cancer in Men Aged 40 to 85
Observational Study to Compare Diagnostic Accuracy and Follow-Up Outcomes
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Metastasis-directed radiotherapy (MDRT) for men with de novo, oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial (METANOVA): protocol for a multicentre, phase II randomised controlled trial in the USA.
Samuel Lichtman-Mikol, Joshua M Lang, Himanshu Nagar...